查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1997391

基因组学人工智慧市场：2026-2032年全球市场预测（按人工智慧技术、服务、序列类型、应用和最终用户划分）

Artificial Intelligence in Genomics Market by AI Technique, Service, Sequencing Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因组学领域的人工智慧市场价值将达到 5.2332 亿美元，到 2026 年将成长到 5.5677 亿美元，到 2032 年将达到 8.5443 亿美元，复合年增长率为 7.25%。

主要市场统计数据
基准年 2025 5.2332亿美元
预计年份：2026年 5.5677亿美元
预测年份 2032 8.5443亿美元
复合年增长率 (%) 7.25%

先进的计算模型、高通量定序和数据工程的融合如何重新定义基因组学中的发现、诊断和治疗决策。

人工智慧正透过将演算法的严谨性与生物学洞见结合，迅速变革基因组学，使以往无法实现的发现成为可能。模型架构的进步、註释资料集的广泛应用以及云端原生运算生态系统的蓬勃发展，都促进了基因组讯号解读的快速与精准。计算方法与高通量定序的融合，正在为理解遗传变异、识别治疗标靶以及将分子特征转化为临床可操作的决策提供新的途径。

一种新的演算法架构、从定序到分析的整合工作流程以及联邦协作模型，在优先考虑合规性和检验的同时，加速了实用化。

基因组学领域正经历着变革性的转变，这主要得益于模型处理能力的提升、多模态资料集的日益丰富以及端到端运算流程的日趋成熟。深度学习架构，包括卷积神经网络和循环神经网络，已被广泛应用于需要空间模式识别和时间序列解释的任务；而自编码器则有助于降维和潜在表征学习，从而揭示隐藏的生物学关係。机器学习范式，例如监督学习和无监督学习，仍然是分类和丛集任务的基础；强化学习也开始应用于高通量环境下的实验设计和资源分配。应用于生物医学文献和临床记录的自然语言处理技术正在改善资讯搜寻并加速假设生成。

美国累积关税措施对基因组学领域的供应链、筹资策略、合作研究实践和国内创新重点的定性影响。

2025年美国关税政策的发展为基因组学领域的供应链、采购决策和研究合作带来了一系列复杂的定性压力。这些压力累积，导致跨境采购的敏感度显着增强，促使各机构重新审视供应商选择标准，并评估试剂、仪器和计算资源供应管道的韧性。实际上，这正在加速许多相关人员寻求供应商多元化，并探索关键耗材和仪器的本土化生产和区域製造伙伴关係。

基于细分的洞察，了解应用需求、演算法方法、服务模型、定序方法和最终用户优先顺序如何决定基因组人工智慧的采用路径。

从精细的细分观点，基因组人工智慧在临床、农业和商业应用等不同领域中最具实际价值的体现方式。在应用领域，农业和动物基因组学正受益于演算法性状选择和基因组选择技术，这些技术加速了作物改良和牲畜育种，使育种者能够更有效地优先考虑产量、适应性和抗病性。诊断领域涵盖临床诊断实验室和调查诊断团队。人工智慧透过改进变异解读和缩短结果获取时间来补充高通量检测，而调查诊断则利用模式发现来产生用于后续检验的假设。在药物发现领域，计算方法扩展到先导化合物识别、标靶检验和临床前试验，人工智慧模型有助于增强虚拟筛检、预测脱靶效应和优化实验优先顺序。精准医疗整合了伴随诊断、个人化治疗和药物基因体学，基于结合基因组和临床数据识别出的预测性生物标记来优化治疗方案。

区域市场动态影响美洲、欧洲、中东和非洲以及亚太地区的基因组人工智慧的商业化、监管和合作研究。

地理趋势正显着影响全球基因组学生态系统中的投资模式、法规环境和合作研究。在美洲，产业界、学术界和临床系统之间持续保持紧密的合作，成熟的创业投资网络为转化研究提供支持，而强大的云端分析基础设施也为之奠定了基础。这种环境正在推动人工智慧驱动工具的快速商业化，但也面临着许多挑战，例如监管力度加大以及对资料安全和病患知情同意框架日益重视。

成熟的平台公司、专业设备製造商、云端服务供应商和创新Start-Ups如何透过伙伴关係、检验和营运弹性来建立其竞争格局。

人工智慧驱动的基因组学领域的竞争动态由成熟的平台公司、专业仪器製造商、云端运算服务供应商以及新兴Start-Ups共同塑造，这些公司将专业知识与创新演算法方法相结合。成熟的平台公司提供定序、分析和支援服务的整合解决方案，而专业仪器製造商则专注于提高通量、准确性和耗材的成本效益。云端运算服务供应商支援可扩展的模型训练和推理，降低了缺乏大规模本地基础设施的机构的进入门槛。

为高阶主管提供切实可行的、循序渐进的策略建议，以确保他们透过资料管治、供应链弹性、模组化架构和道德管治，从基因组学中的人工智慧中获取价值。

产业领导者应采取务实且循序渐进的方式将人工智慧融入基因组学，在创新与营运严谨性之间取得平衡。首先，应明确与组织能力和监管限制相符的高影响力应用案例，并优先投资于能够在这些案例中产生可复製价值的项目。初期工作应着重于建立健全的资料管理、来源追踪和标註标准，以便利用可靠且文件齐全的资料集训练模型。

混合研究框架结合了专家访谈、文献整合、独立基准测试、情境分析和伦理管治审查，以确保获得稳健且可操作的见解。

本分析的调查方法结合了定性专家访谈、技术文献的系统评估以及相关人员访谈检验，从而得出全面且平衡的结论。关键见解来自于与来自学术界、临床诊断、设备製造和软体开发等各领域的专家的结构化对话。除访谈外，对同行评审文章、技术预印本、监管指导文件和公开产品规格的严格审查，确保了技术评估基于最新证据。

整合技术可能性和操作挑战：展示数据品质、互通性和协作检验将如何决定基因组人工智慧在现实世界中的影响。

人工智慧正在革新基因组学，它提高了生物学假设的生成、检验和实用化的速度和准确性。这项技术能够实现更精准的农业育种、更快更准确的诊断、更简化的药物研发流程以及日益个人化的治疗策略。然而，进步并非仅仅源自于更复杂的模型。它同样取决于资料的品质、定序平台和分析工具之间的互通性，以及能够适应监管和供应链波动的稳健营运实务。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人工智慧技术在基因体学领域的市场

  • 深度学习
    • 自编码器
    • 卷积类神经网路
    • 循环神经网络
  • 机器学习
    • 强化学习
    • 监督式学习
    • 无监督学习
  • 自然语言处理
    • 情绪分析
    • 文字探勘

第九章：基因组学领域的人工智慧市场：按服务分类

  • 生物资讯服务
    • 註解
    • 数据分析
    • 解释
  • 咨询
    • 实施支持
    • 战略制定
  • 定序服务
    • EXOME定序
    • 转录组序列
    • 全基因组定序
  • 软体平台
    • 基于云端的
    • 现场

第十章：人工智慧市场类型—基因组定序

  • 次世代定序
    • Illumina
    • Ion Torrent
    • PacBio
  • 桑格定序
    • 微血管
    • 萤光法

第十一章：基因体学领域的人工智慧市场：按应用划分

  • 农业和动物基因组学
    • 作物改良
    • 畜牧养殖
  • 诊断
    • 临床诊断
    • 研究诊断
  • 药物发现
    • 先导化合物的鑑定
    • 临床前试验
    • 目标检验
  • 精准医疗
    • 伴随诊断
    • 个人化治疗
    • 药物基因体学

第十二章：基因组学领域的人工智慧市场：按最终用户划分

  • 学术研究和调查
    • 研究机构
    • 大学
  • 医院和诊所
    • 诊断检查室
    • 医疗中心
  • 製药和生物技术
    • 生技公司
    • 大型製药企业

第十三章：基因体学领域的人工智慧市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：基因组学领域的人工智慧市场：按群体划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：基因组学领域的人工智慧市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国基因体学领域的人工智慧市场

第十七章：中国基因组学领域的人工智慧市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BenevolentAI Ltd.
  • BGI Genomics Co., Ltd
  • Bio-Rad Laboratories, Inc.
  • Data4Cure Inc.
  • Deep Genomics Inc.
  • DNAnexus Inc.
  • Engine Biosciences Pte. Ltd.
  • Exscientia
  • F. Hoffmann-La Roche Ltd
  • Fabric Genomics Inc.
  • FDNA Inc.
  • Freenome Holdings, Inc.
  • Genomics AI
  • Genoox Ltd.
  • Illumina, Inc.
  • insitro
  • International Business Machines Corporation
  • NanoString Technologies, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • SOPHiA Genetics SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-501246436E27

The Artificial Intelligence in Genomics Market was valued at USD 523.32 million in 2025 and is projected to grow to USD 556.77 million in 2026, with a CAGR of 7.25%, reaching USD 854.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 523.32 million
Estimated Year [2026] USD 556.77 million
Forecast Year [2032] USD 854.43 million
CAGR (%) 7.25%

How the convergence of advanced computational models, high-throughput sequencing, and data engineering is redefining discovery, diagnostics, and therapeutic decisions in genomics

Artificial intelligence is rapidly reshaping genomics by combining algorithmic rigor with biological insight to enable discoveries that were previously impractical. Advances in model architectures, increased availability of annotated datasets, and cloud-native compute ecosystems have collectively increased the speed and fidelity with which genomic signals can be interpreted. The convergence of computational methods and high-throughput sequencing has created new modalities for understanding genetic variation, identifying therapeutic targets, and translating molecular signatures into clinically actionable decisions.

Across applications, AI-driven approaches are enhancing capabilities in crop improvement and livestock breeding by enabling more precise trait selection and accelerated breeding cycles, while diagnostics benefit from improved pattern recognition across clinical and research-focused assays to reduce interpretation latency. In drug discovery, computational models are streamlining lead identification, refining target validation, and improving the efficiency of preclinical testing. Within precision medicine, predictive algorithms are informing companion diagnostic development, shaping personalized therapeutic strategies, and supporting pharmacogenomic decision-making.

This introduction frames the remainder of the executive summary by emphasizing the interplay between algorithmic innovation, data fidelity, and service delivery. It underscores that sustained progress will depend on robust annotation and interpretation practices, integration across sequencing platforms, and the alignment of stakeholders in academia, clinical settings, and industry. As a result, leaders must consider both technological opportunity and operational complexity when integrating AI into genomics workflows.

Emerging algorithmic architectures, integrated sequencing-to-analysis workflows, and federated collaboration models that are accelerating translation while raising compliance and validation priorities

The genomic landscape is undergoing transformative shifts driven by deeper model capacity, richer multimodal datasets, and the maturation of end-to-end computational pipelines. Deep learning architectures, including convolutional and recurrent networks, are now routinely applied to tasks that require spatial pattern recognition and temporal sequence interpretation, while autoencoders facilitate dimensionality reduction and latent representation learning that uncover hidden biological relationships. Machine learning paradigms such as supervised and unsupervised learning continue to underpin classification and clustering tasks, and reinforcement learning is beginning to inform experimental design and resource allocation in high-throughput settings. Natural language processing techniques applied to biomedical literature and clinical notes are improving information retrieval and accelerating hypothesis generation.

These methodological shifts are paralleled by service innovation. Bioinformatics services are becoming more modular and cloud-integrated, enabling annotation pipelines and interpretation engines to be consumed as scalable services rather than bespoke projects. Sequencing services are increasingly coupled to analytic platforms so that exome, transcriptome, and whole genome outputs flow directly into validated computational workflows. Consulting practices are transitioning from implementation-only engagements to strategic partnerships that encompass data governance, model validation, and deployment pipelines.

Operationally, the industry is moving toward a more federated model of collaboration where academic institutions, clinical laboratories, and commercial entities share curated datasets through controlled-access mechanisms. This shift reduces duplication of effort, accelerates model training, and enhances reproducibility. At the same time, demand for explainability, provenance tracking, and regulatory compliance is rising, prompting the adoption of standardized ontologies, versioned pipelines, and rigorous validation frameworks. Collectively, these transformative shifts are enabling faster translation of genomic insights into practical applications while raising the bar for quality assurance and ethical stewardship.

Qualitative implications of cumulative U.S. tariff measures on supply chains, procurement strategies, collaborative research practices, and domestic innovation priorities within genomics

U.S. tariff policy dynamics in 2025 have introduced a complex set of qualitative pressures across supply chains, procurement decisions, and research collaborations in genomics. The cumulative effect has been to increase sensitivity to cross-border sourcing, encouraging institutions to revisit vendor selection criteria and to evaluate the resilience of reagent, instrument, and compute supply channels. In practice, this has led many stakeholders to accelerate efforts to diversify suppliers and to explore onshoring or regional manufacturing partnerships for critical consumables and instruments.

From a procurement perspective, higher import levies and administrative friction have incentivized larger organizations to negotiate longer-term contracts to secure price stability, while smaller laboratories and research groups have sought collaborative purchasing consortia or alternative sourcing strategies to mitigate cost volatility. These behaviors are reshaping supplier relationships and shifting commercial conversations toward total cost of ownership, lead time guarantees, and service-level commitments.

Research collaborations and data-sharing arrangements have also adapted. Where cross-border projects previously relied on rapid reagent resupply and instrument service agreements, teams are now placing greater emphasis on data portability and remote analysis capabilities as contingency mechanisms. Cloud-native analysis platforms and software-as-a-service offerings have become essential for maintaining continuity when physical components face tariff-driven delays. At the same time, concerns around intellectual property and data localization have grown, prompting more rigorous contractual frameworks and a renewed focus on local regulatory compliance.

On the innovation front, tariff-induced pressures have spurred domestic investment in alternative technologies, including production of sequencing consumables, modular instrumentation designs that are easier to source locally, and software platforms that reduce reliance on proprietary hardware. While these shifts do not eliminate the tradeoffs associated with specialization and economies of scale, they are reshaping competitive positioning and encouraging new entrants focused on cost-effective domestic solutions. Ultimately, the cumulative impact of tariffs in 2025 has been to accelerate strategic reassessment of supply chains, strengthen the value of integrated analytic services, and increase the importance of operational resilience in genomics workflows.

Segmentation-driven insight into how application needs, algorithmic approaches, service models, sequencing modalities, and end-user priorities determine adoption pathways in genomic AI

A granular segmentation lens reveals where AI in genomics is generating the most actionable value across distinct clinical, agricultural, and commercial contexts. In application domains, agriculture and animal genomics benefit from algorithmic trait selection and genomic selection methods that accelerate crop improvement and livestock breeding, enabling breeders to prioritize yield, resilience, and disease resistance more effectively. Diagnostics encompasses both clinical diagnostic labs and research diagnostics teams; AI complements high-throughput assays by improving variant interpretation and reducing turnaround, while research diagnostics leverage pattern discovery to generate hypotheses for downstream validation. In drug discovery, computational approaches span lead identification, target validation, and preclinical testing, with AI models enhancing virtual screening, predicting off-target effects, and optimizing experimental prioritization. Precision medicine integrates companion diagnostics, personalized therapeutics, and pharmacogenomics to tailor treatments based on predictive biomarkers identified through combined genomic and clinical data.

Regarding AI techniques, advances in deep learning-encompassing autoencoders, convolutional neural networks, and recurrent neural networks-are particularly impactful for sequence-based pattern recognition and representation learning. Machine learning subfields such as supervised, unsupervised, and reinforcement learning remain core to classification, clustering, and optimized experimental strategies. Natural language processing techniques, applied to literature mining and clinical text, facilitate rapid curation of evidence and support translational research by extracting actionable insights from unstructured sources.

Service-oriented segmentation underscores the importance of integrated offerings. Bioinformatics services that deliver annotation, data analysis, and interpretation are foundational for transforming raw sequences into interpretable results. Consulting engagements that address implementation support and strategy development help organizations align technical deployments with clinical and commercial objectives. Sequencing services-spanning exome sequencing, transcriptome sequencing, and whole genome sequencing-feed downstream analytics, while software and platform choices, whether cloud-based or on-premise, determine scalability, data governance, and latency profiles.

Sequencing modality distinctions matter for both analytic pipelines and procurement. Next generation sequencing platforms such as Illumina, Ion Torrent, and PacBio deliver varied read lengths, throughput, and error profiles that influence model training and interpretation strategies. Sanger sequencing, with capillary and fluorescence modalities, continues to serve as a validation and targeted analysis approach. End-user segmentation further differentiates adoption patterns: academic and research institutions, including research institutes and universities, prioritize methodological openness and reproducibility; hospitals and clinics, including diagnostic laboratories and medical centers, emphasize regulatory compliance, turnaround time, and integration with clinical workflows; and pharma and biotech organizations, both biotech firms and large pharmaceutical companies, require scalable pipelines, IP protection, and regulatory-grade validation to support drug development and companion diagnostic strategies.

Taken together, these segmentation insights illustrate that successful AI adoption in genomics requires a nuanced alignment of technique selection, service model, sequencing modality, and end-user priorities. Solutions tailored to the specific combination of application needs and operational constraints will achieve higher adoption and greater downstream impact.

Regional market dynamics shaping commercialization, regulation, and collaborative research in genomic AI across the Americas, EMEA, and Asia-Pacific landscapes

Geographic dynamics materially influence investment patterns, regulatory environments, and collaborative behaviors across the global genomics ecosystem. The Americas continue to demonstrate a strong integration between industry, academic centers, and clinical systems, with mature venture capital networks supporting translational initiatives and robust infrastructure for cloud-based analytics. This environment favors rapid commercialization of AI-driven tools, although it also faces heightened regulatory scrutiny and increasing emphasis on data security and patient consent frameworks.

Europe, Middle East & Africa presents a diverse regulatory mosaic where harmonization efforts coexist with country-level variability in reimbursement and clinical adoption pathways. Public sector investment in genomics and collaborative consortia is a notable feature, and the region places strong emphasis on data protection, ethical governance, and interoperability standards. These priorities shape vendor strategies, encouraging solutions that prioritize privacy-preserving analytics, transparent provenance, and compliance with local health authority requirements.

Asia-Pacific is characterized by a mix of high-throughput sequencing capacity, strong domestic manufacturing in certain markets, and accelerating public-private partnerships that drive large-scale genomic initiatives. Rapid adoption in clinical genomics and agriculture is supported by governments seeking to leverage genomics for national health and food security goals. The region also demonstrates a growing ecosystem of AI talent and cloud infrastructure providers, which together enable localized innovation, faster iteration cycles, and competitive alternatives to incumbent suppliers.

Across these regions, cross-border collaborations persist but are increasingly mediated by considerations of data sovereignty, supply chain resilience, and regulatory alignment. Regional strategies that account for local procurement practices, clinical validation requirements, and cultural expectations around data use will have a distinct advantage in both market penetration and sustained impact.

How platform incumbents, specialized instrument makers, cloud providers, and innovative startups are structuring the competitive landscape through partnerships, validation, and operational resilience

Competitive dynamics in AI-enabled genomics are defined by a mix of platform incumbents, specialized instrument makers, cloud and compute providers, and emerging startups that combine domain expertise with novel algorithmic approaches. Platform incumbents bring integrated solutions that bundle sequencing, analytics, and support services, while specialized instrument manufacturers focus on improvements in throughput, accuracy, and consumable economics. Cloud and compute providers enable scalable model training and inference, lowering barriers for organizations without extensive on-premise infrastructure.

Startups and specialist vendors are differentiating through novel model architectures, targeted datasets, and service offerings that address specific pain points such as clinical-grade interpretability, low-resource deployment, and edge-enabled analytics for decentralized testing. Partnerships between instrument manufacturers and software providers are increasingly common, reflecting the industry preference for end-to-end validated solutions that reduce integration risk for end users. Academic spinouts and consortium-driven initiatives continue to feed the innovation pipeline, often partnering with commercial entities to move discoveries through validation and regulatory pathways.

Successful companies are those that combine technical excellence with reproducible validation regimes, strong data governance practices, and clear value propositions for distinct end users. Firms that invest in transparent model documentation, rigorous benchmarking against independent datasets, and collaborative trials with clinical or agricultural partners are better positioned to overcome adoption barriers. Equally important are strategic alliances that secure supply chain continuity and regional presence, as these operational factors are increasingly influential in procurement decisions.

Practical and phased strategic recommendations for executives to secure value from AI in genomics through data governance, supply resilience, modular architectures, and ethical stewardship

Industry leaders should adopt a pragmatic, phased approach to integrating AI into genomics that balances innovation with operational rigor. Start by defining high-impact use cases that align with organizational capabilities and regulatory constraints, and then prioritize investments that deliver reproducible value within those use cases. Early efforts should focus on establishing robust data curation, provenance tracking, and annotation standards to ensure that models are trained on reliable, well-documented datasets.

Leaders should also develop a hybrid sourcing strategy that mitigates supply chain risk by combining regional suppliers, long-term contracts for critical consumables, and cloud-based failover options for compute and analytics. Strategic partnerships with academic centers and clinical laboratories can accelerate validation and provide access to diverse datasets, while consulting engagements can bridge capability gaps during implementation.

From a technology perspective, adopt modular architectures that allow teams to swap model components and sequencing inputs without disrupting validated workflows. Emphasize explainability and documentation to facilitate regulatory review and clinician acceptance, and invest in continuous monitoring and post-deployment validation to detect model drift and maintain performance. Finally, embed ethical governance and privacy-preserving techniques into program design to build trust with patients, regulators, and commercial partners. These steps will help organizations capture the benefits of AI while managing the operational and reputational risks inherent in genomics applications.

A mixed-methods research framework combining expert interviews, literature synthesis, independent benchmarking, scenario analysis, and ethical governance review to ensure robust actionable insights

The research methodology underpinning this analysis combined qualitative expert elicitation, systematic evaluation of technical literature, and validation through stakeholder interviews to ensure comprehensive and balanced conclusions. Primary insights were derived from structured conversations with domain experts spanning academia, clinical diagnostics, instrument manufacturing, and software development. These interviews were complemented by a rigorous review of peer-reviewed studies, technical preprints, regulatory guidance documents, and publicly disclosed product specifications to ground technical assessments in current evidence.

Analytic rigor was maintained through cross-validation of algorithmic claims against independent benchmarking datasets and by applying reproducibility checks to reported model architectures and performance metrics. Service and commercialization insights were triangulated using procurement case studies, vendor documentation, and practical implementation reports to capture real-world constraints. The analysis also included scenario-based thinking to explore operational responses to external pressures such as supply chain disruptions and evolving regulatory expectations.

Ethical and privacy considerations were explicitly integrated into the methodology. This involved evaluating data governance frameworks, consent mechanisms, and privacy-preserving computational techniques such as federated learning or secure enclaves. Limitations and areas of uncertainty were documented to help readers assess the contextual applicability of the findings and to identify priorities for additional primary research or pilot engagements.

Synthesis of technological promise and operational imperatives showing how data quality, interoperability, and collaborative validation determine real-world impact in genomic AI

AI is catalyzing a step-change in genomic science by improving the speed and fidelity with which biological hypotheses are generated, validated, and translated. The technology is enabling more precise agricultural breeding, faster and more accurate diagnostics, streamlined drug discovery workflows, and increasingly personalized therapeutic strategies. Progress, however, is not merely a function of model sophistication; it depends equally on data quality, interoperability between sequencing platforms and analytic tools, and resilient operational practices that accommodate regulatory and supply chain variability.

Looking ahead, organizations that combine technical rigor with pragmatic operational strategies-strong data stewardship, modular technical architectures, regional supply diversification, and transparent validation practices-will be best positioned to realize sustained impact. Collaboration across academia, clinical systems, industry, and policy makers will remain essential to align incentives, accelerate validation cycles, and ensure that ethical and privacy considerations are not sidelined in the pursuit of technological advancement. By attending to both the scientific and operational dimensions of AI integration, stakeholders can translate computational promise into robust, real-world genomic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Genomics Market, by AI Technique

  • 8.1. Deep Learning
    • 8.1.1. Autoencoders
    • 8.1.2. Convolutional Neural Networks
    • 8.1.3. Recurrent Neural Networks
  • 8.2. Machine Learning
    • 8.2.1. Reinforcement Learning
    • 8.2.2. Supervised Learning
    • 8.2.3. Unsupervised Learning
  • 8.3. Natural Language Processing
    • 8.3.1. Sentiment Analysis
    • 8.3.2. Text Mining

9. Artificial Intelligence in Genomics Market, by Service

  • 9.1. Bioinformatics Services
    • 9.1.1. Annotation
    • 9.1.2. Data Analysis
    • 9.1.3. Interpretation
  • 9.2. Consulting
    • 9.2.1. Implementation Support
    • 9.2.2. Strategy Development
  • 9.3. Sequencing Services
    • 9.3.1. Exome Sequencing
    • 9.3.2. Transcriptome Sequencing
    • 9.3.3. Whole Genome Sequencing
  • 9.4. Software & Platform
    • 9.4.1. Cloud-Based
    • 9.4.2. On-Premise

10. Artificial Intelligence in Genomics Market, by Sequencing Type

  • 10.1. Next Generation Sequencing
    • 10.1.1. Illumina
    • 10.1.2. Ion Torrent
    • 10.1.3. PacBio
  • 10.2. Sanger Sequencing
    • 10.2.1. Capillary
    • 10.2.2. Fluorescence

11. Artificial Intelligence in Genomics Market, by Application

  • 11.1. Agriculture & Animal Genomics
    • 11.1.1. Crop Improvement
    • 11.1.2. Livestock Breeding
  • 11.2. Diagnostics
    • 11.2.1. Clinical Diagnostics
    • 11.2.2. Research Diagnostics
  • 11.3. Drug Discovery
    • 11.3.1. Lead Identification
    • 11.3.2. Preclinical Testing
    • 11.3.3. Target Validation
  • 11.4. Precision Medicine
    • 11.4.1. Companion Diagnostics
    • 11.4.2. Personalized Therapeutics
    • 11.4.3. Pharmacogenomics

12. Artificial Intelligence in Genomics Market, by End User

  • 12.1. Academic & Research
    • 12.1.1. Research Institutes
    • 12.1.2. Universities
  • 12.2. Hospitals & Clinics
    • 12.2.1. Diagnostic Laboratories
    • 12.2.2. Medical Centers
  • 12.3. Pharma & Biotech
    • 12.3.1. Biotech Firms
    • 12.3.2. Large Pharma

13. Artificial Intelligence in Genomics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Intelligence in Genomics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Intelligence in Genomics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Intelligence in Genomics Market

17. China Artificial Intelligence in Genomics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. BenevolentAI Ltd.
  • 18.7. BGI Genomics Co., Ltd
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. Data4Cure Inc.
  • 18.10. Deep Genomics Inc.
  • 18.11. DNAnexus Inc.
  • 18.12. Engine Biosciences Pte. Ltd.
  • 18.13. Exscientia
  • 18.14. F. Hoffmann-La Roche Ltd
  • 18.15. Fabric Genomics Inc.
  • 18.16. FDNA Inc.
  • 18.17. Freenome Holdings, Inc.
  • 18.18. Genomics AI
  • 18.19. Genoox Ltd.
  • 18.20. Illumina, Inc.
  • 18.21. insitro
  • 18.22. International Business Machines Corporation
  • 18.23. NanoString Technologies, Inc.
  • 18.24. PerkinElmer, Inc.
  • 18.25. QIAGEN N.V.
  • 18.26. SOPHiA Genetics SA
  • 18.27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AUTOENCODERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AUTOENCODERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AUTOENCODERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SENTIMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SENTIMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SENTIMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TEXT MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TEXT MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TEXT MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ANNOTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ANNOTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ANNOTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY INTERPRETATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY INTERPRETATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY INTERPRETATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY IMPLEMENTATION SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY IMPLEMENTATION SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY IMPLEMENTATION SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY STRATEGY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY STRATEGY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY STRATEGY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ON-PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ON-PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ILLUMINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ILLUMINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ILLUMINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ION TORRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ION TORRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PACBIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PACBIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PACBIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CAPILLARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CAPILLARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CAPILLARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY FLUORESCENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY FLUORESCENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY FLUORESCENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LEAD IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LEAD IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LEAD IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TARGET VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY TARGET VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PERSONALIZED THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PERSONALIZED THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PERSONALIZED THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MEDICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MEDICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MEDICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOTECH FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOTECH FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PRECISION MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY ACADEMIC & RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY PHARMA & BIOTECH, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AI TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SERVICE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SOFTWARE & PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SEQUENCING TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY SANGER SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN GENOMICS MARKET SIZE, BY AGRICULTURE & ANIMAL GENOMICS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRIC